Status:

UNKNOWN

Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML

Lead Sponsor:

The Korean Society of Pediatric Hematology Oncology

Conditions:

Acute Myeloid Leukemia

Eligibility:

All Genders

1-21 years

Phase:

PHASE1

PHASE2

Brief Summary

Cord blood transplantation (CBT) is an alternative option for patients with pediatric acute leukemia that indicated stem cell transplantation. Although CBT is as affective as unrelated bone marrow tra...

Detailed Description

Since the first successful transplantation using umbilical cord blood (UCB) to treat a patient with Fanconi anemia in 1988 (Gluckman E, 1989), cord blood transplantation (CBT) has become an alternativ...

Eligibility Criteria

Inclusion

  • Diagnosis of acute myeloid leukemia (FAB or WHO classification).
  • Indicated for hematopoietic stem cell transplantation.
  • Age: \< 21 years old.
  • Performance status: ECOG 0-2.
  • Patients must be free of significant functional deficits in major organs, but the following eligibility criteria may be modified in individual cases. 1. Heart: a shortening fraction \> 30%, ejection fraction \> 45%. 2. Liver: total bilirubin \< 2 × upper limit of normal; ALT \< 3 × upper limit of normal. 3. Kidney: creatinine \<2 × normal or a creatinine clearance (GFR) \> 60 ml/min/1.73m2.
  • Patients must lack any active viral infections or active fungal infection.
  • Appropriate cord blood unit is available: accept HLA mismatch in two of six loci (pairs of A, B, and DR). Allow 2 units cord transplantation.
  • One of parents should sign informed consent.

Exclusion

  • Pregnant or nursing women.
  • Malignant (except acute myeloid leukemia) or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy.
  • Psychiatric disorder that would preclude compliance.
  • More than three HLA type mismatch.
  • T cell depleted or ex vivo expanded cord blood.

Key Trial Info

Start Date :

June 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2012

Estimated Enrollment :

35 Patients enrolled

Trial Details

Trial ID

NCT00887042

Start Date

June 1 2006

End Date

May 1 2012

Last Update

March 26 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Seoul National University Hospital

Seoul, Chongno-gu, South Korea, 110-744

Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML | DecenTrialz